慢性鼻窦炎伴鼻息肉生物制剂治疗的最新综述
该综述通过PRISMA检索筛选出7项符合严格设计的2/3期临床试验,比较了dupilumab、mepolizumab和omalizumab在治疗严重CRSwNP中的疗效。结果显示三种生物制剂效应量均较大,能显著减轻患者症状负担,其中dupilumab对嗅觉丧失的改善尤为明显。但因研究异质性大,直接比较困难,需真实世界注册研究和比较试验进一步验证。
要点
- dupilumab、mepolizumab和omalizumab在严重CRSwNP中均显示较大效应量,可显著减轻症状负担。
- dupilumab对患者相关和非患者相关嗅觉参数均有显著改善。
- 因纳入标准、结局参数和分析时间点差异,三种生物制剂直接比较具有挑战性。
核心结论
- 尽管生物制剂试验方案、剂量和分析时间点存在异质性,本综述全面展示了生物制剂治疗CRSwNP的结局。
- dupilumab、mepolizumab和omalizumab的效应量足以反映难治性CRSwNP患者症状负担的大幅减轻。
研究设计与样本
- 通过PRISMA检索,从所有可用的2期和3期临床试验中严格筛选出设计最严谨且兼容的研究。
- 筛选标准包括明确CRSwNP定义、至少两种给药剂量、可比的时间框架和相同的结局参数。
- 最终保留7项对dupilumab、mepolizumab和omalizumab具有显著数据的研宄。
- 疗效评估选择的治疗持续时间为16至25周。
主要发现
- dupilumab、mepolizumab和omalizumab的效应量似乎足够大,反映难治性CRSwNP患者症状负担的大幅减轻。
- dupilumab对患者相关和非患者相关嗅觉丧失参数的效应量均明显显著,反映治疗患者嗅觉损害大幅减轻的临床经验。
关键数值与推荐
- 研究需符合明确的CRSwNP定义、至少两种给药剂量、可比的时间框架和相同的结局参数。
- 评估的结局参数包括患者相关指标(鼻塞、嗅觉丧失和SNOT-22评分)和非患者相关指标(CT扫描Lund-Mackay评分、嗅觉测试和鼻息肉评分)。
- 疗效评估的治疗持续时间为16至25周。
临床怎么用
- 生物制剂可作为严重CRSwNP的附加治疗,dupilumab、mepolizumab和omalizumab均显示较大效应量。
- dupilumab对嗅觉丧失的改善尤为显著,可考虑用于伴有嗅觉损害的患者。
- 需真实世界注册研究、比较试验和/或内型驱动治疗方案来回答仍存在的多个问题。
局限性
- 直接比较dupilumab、mepolizumab和omalizumab的疗效具有挑战性,因纳入标准、结局参数和分析时间点存在差异。
- 生物制剂试验的方案、剂量和分析时间点存在异质性。
- 仍有许多开放问题需真实世界注册研究、比较试验和/或内型驱动治疗方案来回答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The majority of patients with uncontrolled severe CRSwNP, asthma and atopic dermatitis share a similar T helper 2 type inflammation linked to their underlying phenotype. This discovery has triggered new research around treatments targeting specific cytokines driving inflammation in CRSwNP like IL-4, IL-13, IL-5 and IgE. Biologicals are increasingly tested as additional tre- atment for patients suffering from severe chronic rhinosinusitis with nasal polyps (CRSwNP). Their efficacy has been demonstrated in multiple studies. All studies differ in terms of baseline characteristics of included patients and outcome parameters analysed. AIMS: A comparative analysis of the efficacy of reported biologicals for CRSwNP based on the published data for phase 2 and 3 studies. The aim was to provide a comprehensive overview across the different biologicals and outcome parameters. METHODS: In a first step we critically selected out of all available phase 2 and 3 clinical trials the ones containing the most rigorous and compatible study designs. Meaning studies that comply with a need for a clear definition of CRSwNP, at least two administra- tion doses, comparable timeframes and the same outcome parameters studied. This assessment was performed using a PRISMA search. We retained 7 studies with significant data for dupilumab, mepolizumab and omalizumab. In a second step the effect-sizes of treatment with those biologicals were compared for the most important outcome parameters both patient relevant (nasal con- gestion, smell loss and SNOT-22 scores) and patient irrelevant (CT scan Lund-Mackay, smell test and nasal polyp scores). Therapy duration of 16 to 25 weeks was chosen for evaluation of efficacy. RESULTS: A direct comparison of efficacy between dupilumab, mepolizumab and omalizumab is challenging given differences in inclusion criteria, outcome parameters and time-points of analyses. We have been able to conclude that effect sizes of dupilumab, mepolizumab and omalizumab seem large enough to reflect a major reduction in symptom burden as experienced by patients suffering from refractory CRSwNP. The effect size of dupilumab on both patient relevant and patient irrelevant parameters of smell loss are clearly significant and reflect the clinical experience of major reduction of smell impairment in treated patients. CONCLUSION: Despite the heterogeneity of protocols, dosages and time-points of analyses of biological trials in CRSwNP, this over- view highlights outcomes of biological treatment in CRSwNP in a comprehensive way. Real-life registries, comparative trials and/ or endotype-driven treatment plans are needed to provide the answers to the multiple questions that are still open today.
引用
- Hellings PW, Verhoeven E, Fokkens WJ, et al. State-of-the-art overview on biological treatment for CRSwNP. Rhinology. 2021. PMID: 33459728. doi:10.4193/Rhin20.570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。